Cureteq is an asset management and biotechnology company developing innovative medicines based on a sophisticated artificial intelligence platform.
Cureteq leverages artificial intelligence to identify the optimal applications of a given molecule and to de-risk clinical development.
What we do
Cureteq is an asset management and biotechnology company developing innovative medicines based on a sophisticated artificial intelligence platform.
Cureteq leverages artificial intelligence to identify the optimal applications of a given molecule and to de-risk clinical development.
Cureteq est.
Nov 2021
Privately held
10+ Employees
Strategic partners
Innoplexus
Office in Zug
Portfolio company,
Oncoteq est. Apr 2022
Latest news
Meet CBO Sarah Holland at SACHS Biotech Conference, Basel 25-26 Sep 2024
Reach out directly or request meetings via the platform. Looking forward to interesting conversations on partnering and or collaboration
Oncoteq sponsor of Tiffany’s Pink Pedal Ride for Breast Cancer 2024
It was an honor for Oncoteq to sponsor Tiffany’s Pink Pedal Ride, to raise money for the Tiffany Lynn O’Donnell Foundation and Breast Cancer Research, and to commemorate Tiffany Lynn O’Donnell a …
Meeting at J.P. Morgan 2024?
Looking for partnering or investment with Cureteq or Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco
Shortcuts
About Us
Cureteq combines asset management, biotechnology and artificial intelligence in a unique platform to drive assets efficiently and effectively to the next value inflection and beyond. Cureteq est. Nov …
Portfolio
The Cureteq portfolio consists of Oncoteq, focusing on oncology, and a company still in stealth mode. Oncoteq
Platform
The Cureteq platform uniquely combines a fully flexible and agile biotech company-builder model with AI supported drug development
Transforming drug development
We aim to transform drug development and drive assets beyond value inflection points by:
- Unlocking hidden value of unattended molecules through AI
- Combining agility and expertise in a lean structure
- Flexible partnering and financing model